Polygalasaponin F

Polygalasaponin F (PGSF) is an oleanane-type triterpenoid saponin originally isolated from the aerial parts of Polygala japonica Houtt., a perennial herb of the Polygalaceae family used in traditional East Asian medicine for its sedative, expectorant, and cognition-enhancing properties. The compound has a molecular formula of C53H86O23 (molecular weight 1091.2 g/mol) and bears a presqualene-derived oleanane aglycone substituted with a 3-O-beta-D-glucopyranosyl unit and a C-28 ester-linked trisaccharide chain composed of glucopyranose, rhamnopyranose, and xylopyranose residues. PGSF has emerged as a compound of substantial preclinical research interest across multiple neuroprotective and anti-inflammatory domains, supported by a growing body of in vitro and in vivo evidence published principally between 2012 and 2025.

The pharmacological profile of PGSF is characterized by multi-target activity converging on neuronal survival, synaptic plasticity, and neuroinflammatory suppression. In adult rat hippocampal slices, PGSF at 1 to 10 micromolar induces sustained long-term potentiation (LTP) in the dentate gyrus through activation of N-methyl-D-aspartate receptors (NMDARs), with downstream phosphorylation of NR2B, calcium/calmodulin-dependent protein kinase II (CaMKII), extracellular signal-regulated kinase (ERK), and cyclic AMP response element-binding protein (CREB), placing it among a small number of natural saponins with direct electrophysiological evidence of synaptic strengthening. In cultured hippocampal neurons exposed to glutamate excitotoxicity, PGSF produces concentration-dependent neuroprotection by attenuating cytosolic calcium overload and modulating NMDAR subunit expression, specifically preserving NR2A while limiting excess NR2B-mediated calcium influx. In oxygen-glucose deprivation and reoxygenation (OGD/R) models of ischemic injury using PC12 cells and primary cortical neurons, PGSF activates the PI3K/Akt survival signaling pathway, upregulates the Bcl-2/Bax ratio, and suppresses caspase-3 activation to inhibit apoptosis.

The anti-inflammatory pharmacology of PGSF operates through at least two characterized signaling cascades. In lipopolysaccharide-stimulated BV-2 microglial cells, PGSF suppresses tumor necrosis factor alpha (TNF-alpha) release through inhibition of the toll-like receptor 4 (TLR4) to phosphoinositide 3-kinase (PI3K) to protein kinase B (AKT) to nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling axis. In middle cerebral artery occlusion (MCAO) rat models of focal ischemia and reperfusion, PGSF ameliorates neurological deficit, reduces infarct volume, and inhibits the thioredoxin-interacting protein (TXNIP) to NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome signaling pathway. More recent studies (2024 to 2025) have identified additional mechanistic targets: PGSF downregulates the Na-K-2Cl cotransporter 1 (NKCC1) through enhanced DNA methylation, thereby reducing blood-brain barrier disruption and cerebral edema following ischemia-reperfusion, and PGSF alleviates cerebral ischemia-reperfusion injury through inhibition of excessive mitophagy, preserving mitochondrial membrane potential and reducing mitochondrial reactive oxygen species accumulation.

No clinical trials of PGSF in humans have been conducted. The compound remains in the preclinical investigational phase, with the entirety of the evidence base derived from in vitro cell culture systems and rodent models of cerebral ischemia, glutamate excitotoxicity, and neuroinflammation. Pharmacokinetic data specific to PGSF in any species are not available in published form; general considerations for triterpenoid saponin bioavailability (gastrointestinal hydrolysis of glycosidic bonds, limited oral absorption of intact saponin, hepatic first-pass metabolism) apply and represent a translational barrier that has not been formally addressed. The compound is available from multiple research chemical suppliers at greater than 95 percent purity for in vitro and in vivo research applications. This monograph reviews the chemistry, isolation, and structural characterization of PGSF; the multi-target molecular pharmacology across NMDA receptor, PI3K/Akt, TLR4/NF-kB, TXNIP/NLRP3, NKCC1, and mitophagy pathways; the preclinical evidence base in ischemic stroke, glutamate excitotoxicity, and neuroinflammation models; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse events and safety signals from animal studies; and a comparative assessment of five neuroprotective Polygala-derived saponins against PGSF on five competency standards.